{"changes":[],"country":"US","description":"NatsarPharma is developing RK-33, a first-in-class small-molecule DDX3 RNA-helicase inhibitor that arrests G1, induces apoptosis, and sensitises tumours to radiation. It targets DDX3-overexpressing lung, breast, brain, sarcoma, pancreatic, and prostate cancers via biopsy-stratified trials. Spun out of Johns Hopkins, the asset disrupts Wnt signalling and DNA repair simultaneously.","domain":"natsarpharmaceuticals.com","employees":null,"founded":null,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"unknown","investors":[],"lat":39.275736,"lng":-76.831742,"location":"ellicott city, md, usa","name":"NATSAR PHARMACEUTICALS, INC.","rounds":[{"amountQuarantined":false,"amountUsd":1600000,"currency":"USD","date":"2025-01-01","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"sbir","retrievedAt":"2026-05-07","status":"attributed","url":null},"status":"attributed","type":"grant","url":null}],"slug":"natsarpharmaceuticals-com","sources":[{"fact":"round","publisher":"sbir","retrievedAt":"2026-05-07","status":"attributed","url":null},{"fact":"existence","publisher":"natsarpharmaceuticals.com","retrievedAt":"2026-05-07","status":"self-reported","url":"https://natsarpharmaceuticals.com"},{"fact":"description","publisher":"natsarpharmaceuticals.com","retrievedAt":"2026-05-07","status":"self-reported","url":"https://natsarpharmaceuticals.com"}],"stage":null,"techStack":["Cloudflare","reCAPTCHA","Google Font API","Google Hosted Libraries","Google Tag Manager","Webflow","jquery 3.5.1"],"totalRaisedUsd":1600000,"updatedAt":"2026-05-07"}